指南与共识其他结缔组织病类风湿关节炎脊柱关节炎

EULAR关于癌症免疫检查点抑制剂相关风湿免疫不良事件诊疗的考虑要点

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
指南 / 共识 · Ann Rheum Dis · 2020-04-23

该文件由欧洲抗风湿病联盟(EULAR)工作组制定,针对癌症免疫检查点抑制剂(CPI)相关风湿与肌肉骨骼免疫不良事件(irAEs)提出4项总体原则和10项考虑要点。内容涵盖风湿科医生的角色、早期转诊、三类治疗升级策略以及对重症肌炎的警示,并为已有风湿病患者提供基线免疫抑制方案建议。

要点

  • 约10%接受CPI的癌症患者出现风湿与肌肉骨骼irAEs,风湿科医生应参与共同决策。
  • 推荐早期转诊至风湿科以记录靶器官炎症,治疗按局部/全身糖皮质激素、csDMARDs、bDMARDs三级升级。
  • 重症肌炎可危及生命,需大剂量糖皮质激素和密切监测;已有风湿病患者应维持最低有效剂量免疫抑制。

核心结论

  • EULAR考虑要点为风湿性irAEs的诊断和管理提供指导,并旨在支持未来国际合作。

研究设计与样本

  • EULAR工作组先提出研究问题并进行系统文献综述,再基于文献和共识程序制定4项总体原则和10项考虑要点。

主要发现

  • 约10%接受检查点抑制剂的癌症患者出现风湿与肌肉骨骼irAEs。
  • 总体原则明确风湿科医生在irAEs管理中的作用,强调患者、肿瘤科医生和风湿科医生之间的共同决策。
  • 考虑要点提示风湿科医生关注不满足常规风湿病分类标准的广谱肌肉骨骼irAEs及其鉴别诊断。
  • 推荐早期转诊和便利的风湿科就诊以记录靶器官炎症。
  • 治疗定义三级升级:症状未控制时用局部/全身糖皮质激素并逐渐减至最低有效剂量;糖皮质激素反应不足或为减少激素时用传统合成改善病情抗风湿药;重症或难治性irAEs用生物改善病情抗风湿药。

关键数值与推荐

  • 对重症肌炎发出警示,其为危及生命的情况,需要大剂量糖皮质激素和密切监测。
  • 对已有风湿病患者,在开始免疫治疗前应将基线免疫抑制方案维持在最低有效剂量。

临床怎么用

  • 风湿科医生应参与CPI相关irAEs的识别和管理,与肿瘤科医生共同决策。
  • 对疑似风湿性irAEs应早期转诊至风湿科以记录靶器官炎症。
  • 治疗按局部/全身糖皮质激素、csDMARDs、bDMARDs三级升级策略进行。
  • 对重症肌炎应使用大剂量糖皮质激素并密切监测。
  • 已有风湿病患者在开始免疫治疗前应维持基线免疫抑制方案在最低有效剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the lack of guidance for rheumatologists addressing them, a European League Against Rheumatism task force was convened to harmonise expert opinion regarding their identification and management. METHODS: First, the group formulated research questions for a systematic literature review. Then, based on literature and using a consensus procedure, 4 overarching principles and 10 points to consider were developed. RESULTS: The overarching principles defined the role of rheumatologists in the management of irAEs, highlighting the shared decision-making process between patients, oncologists and rheumatologists. The points to consider inform rheumatologists on the wide spectrum of musculoskeletal irAEs, not fulfilling usual classification criteria of rheumatic diseases, and their differential diagnoses. Early referral and facilitated access to rheumatologist are recommended, to document the target organ inflammation. Regarding therapeutic, three treatment escalations were defined: (1) local/systemic glucocorticoids if symptoms are not controlled by symptomatic treatment, then tapered to the lowest efficient dose, (2) conventional synthetic disease-modifying antirheumatic drugs, in case of inadequate response to glucocorticoids or for steroid sparing and (3) biological disease-modifying antirheumatic drugs, for severe or refractory irAEs. A warning has been made on severe myositis, a life-threatening situation, requiring high dose of glucocorticoids and close monitoring. For patients with pre-existing rheumatic disease, baseline immunosuppressive regimen should be kept at the lowest efficient dose before starting immunotherapies. CONCLUSION: These statements provide guidance on diagnosis and management of rheumatic irAEs and aim to support future international collaborations.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kostine M, Finckh A, Bingham CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2020. PMID: 32327425. doi:10.1136/annrheumdis-2020-217139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。